Abstract
Microbial metabolites are remarkable versatile as potent and selective drug lead candidates, and as in situ molecular probes, capable of interrogating key signalling, transport and developmental pathways. Microbial biodiscovery as a drug discovery paradigm has served science and society extremely well, and with appropriate modernisation and reinvestment is well placed to continue to do so into the future. Advances across many disciplines have revealed an untapped silent microbial secondary metabolism, which promises access to unprecedented bioactive chemical space. This renewed capacity can be further enhanced by recognition of the critical importance of widening the search parameters from narrow single bioassay/indication directed programs, to target both active and (seemingly) inactive metabolites, as well as new and known compounds, and a diversity of non-enzymatic chemical transformation products (all too often dismissed as artefacts). Many of the technical and commercial challenges that confronted microbial biodiscovery late last century have been resolved. The need is great and the time is right to re-plumb microbial biodiscovery back into the drug discovery pipeline.
Keywords: Bacteria, fungi, microbial biodiscovery, natural products, non-enzymatic chemical, drug discovery pipeline, key biopolymers, global drug discovery, trillions, Actinomyces, glycopeptides, aminoglycosides, anthelmintic, Penicillium, antilipidemic
Current Topics in Medicinal Chemistry
Title:Microbial Biodiscovery: Back to the Future
Volume: 12 Issue: 14
Author(s): Robert J. Capon
Affiliation:
Keywords: Bacteria, fungi, microbial biodiscovery, natural products, non-enzymatic chemical, drug discovery pipeline, key biopolymers, global drug discovery, trillions, Actinomyces, glycopeptides, aminoglycosides, anthelmintic, Penicillium, antilipidemic
Abstract: Microbial metabolites are remarkable versatile as potent and selective drug lead candidates, and as in situ molecular probes, capable of interrogating key signalling, transport and developmental pathways. Microbial biodiscovery as a drug discovery paradigm has served science and society extremely well, and with appropriate modernisation and reinvestment is well placed to continue to do so into the future. Advances across many disciplines have revealed an untapped silent microbial secondary metabolism, which promises access to unprecedented bioactive chemical space. This renewed capacity can be further enhanced by recognition of the critical importance of widening the search parameters from narrow single bioassay/indication directed programs, to target both active and (seemingly) inactive metabolites, as well as new and known compounds, and a diversity of non-enzymatic chemical transformation products (all too often dismissed as artefacts). Many of the technical and commercial challenges that confronted microbial biodiscovery late last century have been resolved. The need is great and the time is right to re-plumb microbial biodiscovery back into the drug discovery pipeline.
Export Options
About this article
Cite this article as:
J. Capon Robert, Microbial Biodiscovery: Back to the Future, Current Topics in Medicinal Chemistry 2012; 12 (14) . https://dx.doi.org/10.2174/156802612802652394
DOI https://dx.doi.org/10.2174/156802612802652394 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Targeted Therapies in Hepatocellular Carcinoma
Current Medicinal Chemistry Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Cancer Control by Phytochemicals
Current Pharmaceutical Design Strategies for Detecting Genomic DNA Methylation: A Survey of US Patents
Recent Patents on DNA & Gene Sequences Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Targeting Pathways Mediating Bone Disease
Current Pharmaceutical Biotechnology Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling
Current Drug Targets Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Erythropoietin Enhances the Cytotoxic Effect of Hydrogen Peroxide on Colon Cancer Cells
Current Pharmaceutical Biotechnology The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology